Disease · MONDO_0004822
bronchiectasis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. bronchiectasis. Diseases, record MONDO_0004822. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004822
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 2 of its 34 drugs, from ClinicalTrials.gov, EMA Human Drugs and TTD
- Open Targets
Drugs34
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| MANNITOL | CHEMBL689 | Small molecule | Approval | TTD | 5 | 4 | 4 | Drugs and targets |
| BRENSOCATIB | CHEMBL3900409 | Small molecule | Approval | ClinicalTrials.gov and EMA Human Drugs | 5 | 3 | 3 | Drugs and targets |
| CIPROFLOXACIN | CHEMBL8 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 7 | 6 | 6 | Drugs and targets |
| AZITHROMYCIN | CHEMBL529 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ROFLUMILAST | CHEMBL193240 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| TOBRAMYCIN | CHEMBL1747 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| AZTREONAM | CHEMBL158 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets |
| COLISTIMETHATE SODIUM | CHEMBL1201441 | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets | |
| FORMOTEROL | CHEMBL1256786 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 34
See all 34 drugsTargets14
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | 2 | Beta-2 adrenergic receptor agonist | Phase 3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| ELANE | Neutrophil elastase | 2 | Leukocyte elastase inhibitor | Phase 2 | https://conductscience.org/library/genes/1991 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| CFTR | Cystic fibrosis transmembrane conductance regulator | 1 | Cystic fibrosis transmembrane conductance regulator activator | Phase 2 | https://conductscience.org/library/genes/1080 | Drugs and targets |
| CHRM3 | Muscarinic acetylcholine receptor M3 | 1 | Muscarinic acetylcholine receptor M3 antagonist | Unknown | https://conductscience.org/library/genes/1131 | Drugs and targets |
| CTSC | Dipeptidyl peptidase 1 | 1 | Dipeptidyl peptidase I inhibitor | Approval | https://conductscience.org/library/genes/1075 | Drugs and targets |
| IL33 | Interleukin-33 | 1 | Interleukin-33 inhibitor | Phase 2 | https://conductscience.org/library/genes/90865 | Drugs and targets |
| IL5 | Interleukin-5 | 1 | Interleukin-5 inhibitor | Unknown | https://conductscience.org/library/genes/3567 | Drugs and targets |
| IL5RA | Interleukin-5 receptor subunit alpha | 1 | Interleukin-5 receptor subunit alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/3568 | Drugs and targets |
| PDE4A | Phosphodiesterase 4 | 1 | Phosphodiesterase 4 inhibitor | Phase 3 | https://conductscience.org/library/genes/5141 | Drugs and targets |
1 to 10 of 14
See all 14 targetsTrials57
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04594369 | A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis | Phase 3 | 1,767 | 2025-12-16 | Non-Cystic Fibrosis Bronchiectasis | BRENSOCATIB | Its record names the disease | ClinicalTrials.gov |
| NCT02106832 | Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) | Phase 3 | 521 | 2017-09-01 | Bronchiectasis | CIPROFLOXACIN | Its record names the disease | ClinicalTrials.gov |
| NCT00669331 | Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis | Phase 3 | 485 | 2016-04-29 | Bronchiectasis | MANNITOL | Its record names the disease | ClinicalTrials.gov |
| NCT01764841 | Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) | Phase 3 | 416 | 2017-05-24 | Bronchiectasis | CIPROFLOXACIN | Its record names the disease | ClinicalTrials.gov |
| NCT03093974 | Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I) | Phase 3 | 377 | 2023-11-15 | Non Cystic Fibrosis Bronchiectasis | COLISTIMETHATE SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT03460704 | Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium. | Phase 3 | 287 | 2023-12-29 | Non Cystic Fibrosis Bronchiectasis | COLISTIMETHATE SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT01314716 | Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis | Phase 3 | 274 | 2014-04-16 | Bronchiectasis | AZTREONAM | Its record names the disease | ClinicalTrials.gov |
| NCT01313624 | Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis | Phase 3 | 266 | 2014-04-16 | Bronchiectasis | AZTREONAM | Its record names the disease | ClinicalTrials.gov |
| NCT03218917 | Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis | Phase 2 | 256 | 2023-02-08 | Non-Cystic Fibrosis Bronchiectasis | BRENSOCATIB | Its record names the disease | ClinicalTrials.gov |
| NCT02088216 | Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis | Not applicable | 161 | 2019-02-18 | Non-Cystic Fibrosis Bronchiectasis | ACETYLCYSTEINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 57
See all 57 trialsComparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Mannitol vs Control: Safety Profile - Sputum Microbiology | 81 of 233 | 81 of 228 | 461 | NCT00669331 | Trial comparisons |
| Mannitol vs Control: Safety Profile - Hematology | 13 of 233 | 5 of 228 | 461 | NCT00669331 | Trial comparisons |
| Mannitol vs Control: serious adverse events | 43 of 233 | 51 of 228 | 461 | NCT00669331 | Trial comparisons |
| CMS (Colistimethate Sodium) (SAF) vs Placebo (SAF): deaths from any cause | 1 of 176 | 1 of 197 | 373 | NCT03093974 | Trial comparisons |
| CMS (Colistimethate Sodium) (SAF) vs Placebo (SAF): serious adverse events | 31 of 176 | 46 of 197 | 373 | NCT03093974 | Trial comparisons |
| CMS (Colistimethate Sodium) (SAF) vs Placebo (SAF): deaths from any cause | 3 of 152 | 2 of 135 | 287 | NCT03460704 | Trial comparisons |
| CMS (Colistimethate Sodium) (SAF) vs Placebo (SAF): serious adverse events | 27 of 152 | 17 of 135 | 287 | NCT03460704 | Trial comparisons |
| N-acetylcysteine Group vs Control Group: Change of Number of Patients With a Positive Sputum Culture for Pseudomonas Aeruginosa | 8 of 81 | 5 of 80 | 161 | NCT02088216 | Trial comparisons |
| N-acetylcysteine Group vs Control Group: Adverse Events (AEs) (Elevation of Liver Enzymes) | 3 of 81 | 0 of 80 | 161 | NCT02088216 | Trial comparisons |
| N-acetylcysteine Group vs Control Group: Nature of Sputum (Number of Patients With Yellow Purulent) | 12 of 81 | 31 of 80 | 161 | NCT02088216 | Trial comparisons |
1 to 10 of 15
See all 15 comparisons in its trialsPapers from its trials42
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004822
GET https://conductscience.org/api/diseases/v1/MONDO_0004822/drugs?page=2